MK
Therapeutic Areas
Syros Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tamibarotene (SY-1425) | RARA-positive Higher-Risk MDS | Phase 3 |
| SY-2101 | Acute Promyelocytic Leukemia (APL) | Phase 3 |
| SY-5609 | Solid Tumors | Phase 1/2 |
| SY-5007 | RET-altered Solid Tumors | Preclinical |
Leadership Team at Syros Pharmaceuticals
CC
Conley Chee
Chief Executive Officer
DA
David A. Roth
Chief Medical Officer
JH
Jason Haas
Chief Financial Officer
ER
Eric R. Olson
Chief Scientific Officer, Co-founder
KA
Keith A. Katkin
Board Member
NS
Nancy Simonian
Former Chief Executive Officer